FDA ap­proves Ver­ri­ca's skin in­fec­tion treat­ment, en­ters in­to non-bind­ing term sheet for $125M loan

Ver­ri­ca Phar­ma­ceu­ti­cals’ drug-de­vice com­bi­na­tion prod­uct is now the first FDA-ap­proved treat­ment for mol­lus­cum con­ta­gio­sum, a com­mon skin in­fec­tion.

On Fri­day the FDA ap­proved Ycanth, a top­i­cal treat­ment ad­min­is­tered by a health­care provider, for both adults and chil­dren aged 2 years and old­er. The com­pa­ny al­so an­nounced on Mon­day that it en­tered in­to a non-bind­ing term sheet for up to $125 mil­lion in debt fi­nanc­ing to sup­port the launch of Ycanth, or can­tharidin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER